Rigel Pharmaceuticals Stock (NASDAQ:RIGL)
Previous Close
$13.41
52W Range
$7.10 - $17.30
50D Avg
$10.71
200D Avg
$11.68
Market Cap
$234.37M
Avg Vol (3M)
$178.30K
Beta
0.93
Div Yield
-
RIGL Company Profile
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
Product/Service | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|
Revenues from collaborations | $11.49M | - | - |
Discounts and allowances | $-42.76M | $-31.80M | $-18.18M |
Government contracts | $1.10M | - | - |
Gross product sales | $147.06M | $108.52M | $81.19M |
Milestone | $75.00K | - | - |
Product sales, net | $104.29M | $76.72M | $63.01M |
Contract revenues from collaborations | - | $39.02M | $75.73M |
Development milestones | - | $25.00M | $1.88M |
Government contract | - | $4.50M | $10.50M |
License revenues | - | $7.93M | $70.55M |
Research and development services and others | - | $6.09M | $3.30M |
Fiscal year ends in Dec 23 | Currency in USD
Peer Comparison
Ticker | Company |
---|---|
EIGR | Eiger BioPharmaceuticals, Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
NBRV | Nabriva Therapeutics plc |
VECT | VectivBio Holding AG |
MREO | Mereo BioPharma Group plc |
RVPH | Reviva Pharmaceuticals Holdings, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
OCUP | Ocuphire Pharma, Inc. |
FBIO | Fortress Biotech, Inc. |
TERN | Terns Pharmaceuticals, Inc. |
INZY | Inozyme Pharma, Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
IMMX | Immix Biopharma, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
LPTX | Leap Therapeutics, Inc. |
PIRS | Pieris Pharmaceuticals, Inc. |
CDTX | Cidara Therapeutics, Inc. |
ZURA | Zura Bio Limited |
ELEV | Elevation Oncology, Inc. |
ENVB | Enveric Biosciences, Inc. |